Mylan Has Green Light On Remdesivir
Follows Cipla And Hetero Launches Of COVID-19 Treatment
Lauding a “significant milestone for Mylan, for the global public health community and, most importantly, for patients who are battling this pandemic,” Mylan has received approval in India for its remdesivir 100mg/vial product licensed from Gilead Sciences.
You may also be interested in...
Presenting its last ever financial earnings as a standalone company, Mylan revealed plans to host an Investor Day in the first quarter of next year to discuss the strategic direction of Viatris, Mylan’s proposed combination with Pfizer’s Upjohn which is due to close later this month.
Mylan has seen its second-quarter performance echo that of its industry peers, with a lift provided by COVID-19 related demand in the first three months of the year balanced out by declines in the second quarter of 2020.
Mylan says it is closing in on $1bn in cumulative sales of its biosimilars, also disclosing its annual turnover figure from biosimilars as it reported its second-quarter results.